Cercar
01/01/2022
CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study
Munir T., Moreno C., Owen C., Follows G., Benjamini O., Janssens A., Levin M.-D., Osterborg A., Robak T., Simkovic M., Stevens D., Voloshin S., Vorobyev V., Yagci M., Ysebaert L., Qi Q., Steele A., Schuier N., Baeten K., Caces D.B., Niemann C., Kater A.. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:(Q/D).
01/01/2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., Gribben J.G., Kwei K., Dai S., Hsu E., Dean J.P., Flinn I.W.. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9)DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10.100(Q1/2D).
01/01/2022
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8)
Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., El-Cheikh J., Briones J., Gülbas Z., Hamladji R.-M., Elverdi T., Blaise D., Martínez C., Alma E., Halaburda K., Sousa A.B., Glass B., Robinson S., Montoto S., Sureda A.. Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8). LEUKEMIA. 2022; 36(8)DOI:10.1038/s41375-022-01639-5. PMID:35840758. IF:11.400(Q1/1D).
01/01/2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Barr P.M., Owen C., Robak T., Tedeschi A., Bairey O., Burger J.A., Hillmen P., Coutre S.E., Dearden C., Grosicki S., McCarthy H., Li J.-Y., Offner F., Moreno C., Zhou C., Hsu E., Szoke A., Kipps T.J., Ghia P.. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11)DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7.500(Q1/2D).